Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Lebre

Showing results (21-30 of 57) with videos related to

Pageof 6
Sort By:
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|June 30, 2022
ABCB1 restricts brain accumulation of the novel RORγ agonist cintirorgon, while OATP1A/1B and CYP3A limit its oral availabilityWenlong Li, Daniela Lehutová, Rolf W Sparidans, et al.
Toxicology and Applied Pharmacology|March 25, 2024
The ABCB1 and ABCG2 efflux transporters limit brain disposition of the SYK inhibitors entospletinib and lanraplenibNancy H C Loos, Rolf W Sparidans, Paniz Heydari, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|February 1, 2021
The role of drug efflux and uptake transporters ABCB1 (P-gp), ABCG2 (BCRP) and OATP1A/1B and of CYP3A4 in the pharmacokinetics of the CDK inhibitor milciclibAlejandra Martínez-Chávez, Jelle Broeders, Maria C Lebre, et al.
Molecular Pharmaceutics|July 23, 2019
P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral BioavailabilityAlejandra Martínez-Chávez, Stéphanie van Hoppe, Hilde Rosing, et al.
Allergy|June 26, 2003
Analysis of the CD4+ T cell responses to house dust mite allergoidP Kalinski, M C Lebre, D Kramer, et al.
International Journal of Pharmaceutics|December 16, 2018
P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in miceJing Wang, Changpei Gan, Irene A Retmana, et al.
Cancer Chemotherapy and Pharmacology|March 8, 2024
Impact of loperamide on the pharmacokinetics and tissue disposition of ritonavir-boosted oral docetaxel therapy; a preclinical assessmentNancy H C Loos, Viët Bui, Daniëlle H de Jong, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|May 11, 2024
ABCB1 attenuates brain exposure to the KRAS<sup>G12C</sup> inhibitor opnurasib whereas binding to mouse carboxylesterase 1c influences its plasma exposureJamie Rijmers, Irene A Retmana, Viët Bui, et al.
Pharmacological Research|October 26, 2021
ABCB1 and ABCG2 limit brain penetration and, together with CYP3A4, total plasma exposure of abemaciclib and its active metabolitesAlejandra Martínez-Chávez, Nancy H C Loos, Maria C Lebre, et al.
Arthritis and Rheumatism|January 1, 2009
Stimulation of nicotinic acetylcholine receptors attenuates collagen-induced arthritis in miceMarjolein A van Maanen, Maria C Lebre, Tom van der Poll, et al.
Pageof 6

Showing results (21-30 of 57) with videos related to

Sort By:
Pageof 6
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|June 30, 2022
ABCB1 restricts brain accumulation of the novel RORγ agonist cintirorgon, while OATP1A/1B and CYP3A limit its oral availabilityWenlong Li, Daniela Lehutová, Rolf W Sparidans, et al.
Toxicology and Applied Pharmacology|March 25, 2024
The ABCB1 and ABCG2 efflux transporters limit brain disposition of the SYK inhibitors entospletinib and lanraplenibNancy H C Loos, Rolf W Sparidans, Paniz Heydari, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|February 1, 2021
The role of drug efflux and uptake transporters ABCB1 (P-gp), ABCG2 (BCRP) and OATP1A/1B and of CYP3A4 in the pharmacokinetics of the CDK inhibitor milciclibAlejandra Martínez-Chávez, Jelle Broeders, Maria C Lebre, et al.
Molecular Pharmaceutics|July 23, 2019
P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral BioavailabilityAlejandra Martínez-Chávez, Stéphanie van Hoppe, Hilde Rosing, et al.
Allergy|June 26, 2003
Analysis of the CD4+ T cell responses to house dust mite allergoidP Kalinski, M C Lebre, D Kramer, et al.
International Journal of Pharmaceutics|December 16, 2018
P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in miceJing Wang, Changpei Gan, Irene A Retmana, et al.
Cancer Chemotherapy and Pharmacology|March 8, 2024
Impact of loperamide on the pharmacokinetics and tissue disposition of ritonavir-boosted oral docetaxel therapy; a preclinical assessmentNancy H C Loos, Viët Bui, Daniëlle H de Jong, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|May 11, 2024
ABCB1 attenuates brain exposure to the KRAS<sup>G12C</sup> inhibitor opnurasib whereas binding to mouse carboxylesterase 1c influences its plasma exposureJamie Rijmers, Irene A Retmana, Viët Bui, et al.
Pharmacological Research|October 26, 2021
ABCB1 and ABCG2 limit brain penetration and, together with CYP3A4, total plasma exposure of abemaciclib and its active metabolitesAlejandra Martínez-Chávez, Nancy H C Loos, Maria C Lebre, et al.
Arthritis and Rheumatism|January 1, 2009
Stimulation of nicotinic acetylcholine receptors attenuates collagen-induced arthritis in miceMarjolein A van Maanen, Maria C Lebre, Tom van der Poll, et al.
Pageof 6